青光眼用药依从性的成本-效用分析
该研究采用蒙特卡洛微观模拟结合马尔可夫循环(每策略10000次迭代),对40岁及以上青光眼患者进行终身 horizon(最长60年)的成本-效用分析。结果显示,依从患者平均总医疗费用为62782美元(标准差34107),不依从患者为52722美元(标准差38868);不依从患者平均损失0.34个质量调整生命年(QALY),增量成本效果比为每获得1个QALY需29600美元。结论认为,在50000美元/QALY的保守支付意愿阈值下,仍有空间扩大服务以改善患者依从性。
要点
- 不依从患者平均损失0.34个QALY,增量成本效果比为每QALY 29600美元。
- 依从患者平均总医疗费用62782美元(标准差34107),不依从患者52722美元(标准差38868)。
- 在50000美元/QALY的保守支付意愿下,仍有空间扩大服务改善依从性。
核心结论
- 在50000美元/QALY的保守支付意愿阈值下,仍有空间扩大服务以改善患者依从性。
研究设计与样本
- 成本-效用分析,采用蒙特卡洛微观模拟并结合一系列马尔可夫循环,每策略迭代10000次。
- 研究对象为40岁及以上青光眼患者,采用终身 horizon(最长60年)。
主要发现
- 从40岁初诊青光眼开始,不依从患者最早19年进展至单眼盲,依从患者为23年。
- 依从患者平均总医疗费用为62782美元(标准差34107),不依从患者平均为52722美元(标准差38868)。
- 不依从患者平均损失0.34个QALY,增量成本效果比为每获得1个QALY需29600美元。
关键数值与推荐
- 模型设定:较好眼平均偏差为-1.4±-1.9 dB,较差眼为-4.3±-3.4 dB。
- 青光眼恶化者每年累积-0.8 dB损失,稳定者每年损失-0.1 dB。
- 健康状态按平均偏差划分:轻度(≥-6 dB)、中度(<-6至≥-12 dB)、重度(<-12至≥23 dB)、单眼盲(<-20 dB)及双眼盲。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The majority of patients with glaucoma do not take their medications as prescribed. Estimates of the cost-utility value of adherence to prescribed glaucoma medication are vital to implement potentially effective interventions. DESIGN: Cost-utility analysis using Monte Carlo microsimulations incorporating a series of Markov cycles (10 000 iterations per strategy). PARTICIPANTS: Patients with glaucoma aged ≥40 years with a full lifetime horizon (up to 60 years). METHODS: The analysis estimated glaucomatous progression on the basis of data from the United Kingdom Glaucoma Treatment Study. Participants with glaucoma entered the model at age 40 years with a mean deviation in the better-seeing eye of -1.4±-1.9 decibels (dB) and -4.3±-3.4 dB in the worse-seeing eye. Participants whose glaucoma worsened each year accumulate -0.8 dB loss compared with -0.1 dB loss for those who remained stable. Data from the Glaucoma Laser Trial and the Tube versus Trabeculectomy Studies were used to assign probabilities of worsening disease among treated patients. Claims data estimating rates of glaucoma medication adherence over 4 years were used to assign probability of adherence. Those with poor adherence were modeled as having outcomes similar to the placebo arm of the clinical trials. As patients' mean deviation deteriorated, they transitioned between health states from mild (≥-6 dB), to moderate (<-6 to ≥-12 dB), to severe glaucoma (<-12 to ≥23 dB), to unilateral (<-20 dB) and bilateral blindness. At each health state, patients incurred the costs of treatment and established health utilities; ultimately, societal costs of low vision and blindness were included. MAIN OUTCOME MEASURES: Cost and quality-adjusted life year (QALY) of glaucoma medication adherence. RESULTS: Beginning at an initial glaucoma diagnosis at age 40 years, patients proceeded to single-eye blindness as early as 19 years among those who were nonadherent and 23 years for those remaining adherent. Total healthcare costs for adherent patients averaged $62 782 (standard deviation [SD], 34 107), and those for nonadherent patients averaged $52 722 (SD, 38 868). Nonadherent patients had a mean loss of 0.34 QALYs, resulting in a cost-effectiveness ratio of $29 600 per QALY gained. CONCLUSION: At a conservative willingness to pay of $50 000/QALY, there is room to expand services to improve patient adherence.
引用
- Newman-Casey PA, Salman M, Lee PP, et al. Cost-Utility Analysis of Glaucoma Medication Adherence. Ophthalmology. 2019. PMID: 31767436. doi:10.1016/j.ophtha.2019.09.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。